CELL INTELLIGENCE · 肿瘤细胞治疗研究

Inclusion Criteria:

* Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
* Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.

Exclusion Criteria:

Not Applicable

Other protocol-defined inclusion/exclusion criteria apply

主要终点：Incidence of delayed Adverse Events (AEs) · Up to 15 years from last gene-modified (GM) T cell infusion；Persistence of GM T cell drug products · Up to 15 years from last GM T cell infusion；Analysis of vector integration sites · Up to 15 years from last GM T cell infusion；Incidence of replication-competent lentiviruses · Up to 15 years from last GM T cell infusion；Physical growth as assessed by physical examination (pediatric participants only) · Up to 15 years from last GM T cells infusion or until Tanner Stage 5 is reached；Incidence of sexual maturation as assessed by the Tanner staging system (pediatric participants only) · Up to 15 years from last GM T cells infusion or until Tanner Stage 5
次要终点：Lymphocyte count (B-cell)

• Participants exposed to Gene-modified (GM) T cell therapy · OTHER

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.